STOCK TITAN

Aurora Cannabis Inc - ACB STOCK NEWS

Welcome to our dedicated news page for Aurora Cannabis (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aurora Cannabis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aurora Cannabis's position in the market.

Rhea-AI Summary
Aurora Cannabis Inc. achieves Good Manufacturing Practice certification from Australia's Therapeutic Goods Administration for its Canadian production facilities, enhancing its position in the Australian medical cannabis market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.49%
Tags
none
-
Rhea-AI Summary
Aurora Cannabis Inc. and MedReleaf Australia have launched medical cannabis pastilles in Australia, offering greater choice for patients. The pastilles come in three formats, including THC, CBD, and balanced options. MedReleaf Australia aims to provide consistent and high-quality products to Australian patients, with plans for future innovations under the Aurora and IndiMed brands.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.42%
Tags
none
-
Rhea-AI Summary
Aurora Cannabis Inc. announces the repayment of $7.2 million in convertible senior notes, marking a significant milestone in reducing debt. The total cash cost, including accrued interest, amounts to $7.4 million. The remaining debt of $47.9 million is related to Bevo Farms Ltd. CEO Miguel Martin highlights the company's focus on balance sheet strength and financial discipline to achieve positive free cash flow this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
none
Rhea-AI Summary
Aurora Cannabis Inc. partners with Script Assist to empower UK patients with high-quality medical cannabis products and guidance. The partnership aims to enhance the UK medical cannabis landscape by providing access to premium products and valuable information through an innovative technology platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
partnership
-
Rhea-AI Summary
Aurora Cannabis Inc. appoints Simona King, a former Bristol Myers-Squibb executive, as the new Chief Financial Officer. The company also completes a share consolidation on a 10 to 1 basis, with trading under the symbol 'ACB' on NASDAQ and TSX.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.7%
Tags
none
-
Rhea-AI Summary
Aurora Cannabis Inc. re-affirms its commitment to achieving positive free cash flow in 2024 and delivers its fifth consecutive quarter of positive adjusted EBITDA. The company has become the largest global medical cannabis company in nationally legal markets following the acquisition of MedReleaf Australia, and has experienced strong YoY growth in high-margin international net cannabis revenue. They reported a cash position of over $200 million and expect to fully repay remaining convertible debt of $7.3 million in February. The company's fiscal 2024 is on track to be their strongest year yet, with 41% YoY growth in international medical net revenue. They also anticipate achieving positive adjusted EBITDA on an annualized basis for the first time in fiscal 2024. The acquisition of MedReleaf Australia is expected to be immediately accretive to Adjusted EBITDA, while accelerating their path to generate positive free cash flow this calendar year. Aurora expects steady revenue from Canadian medical and consumer segments, modest growth in Europe and Australia, and seasonally higher revenues and gross profit from plant propagation in fiscal Q4 2024. They have repurchased approximately $23.1 million in principal amount of convertible debentures and expect to be debt-free by the end of February 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
earnings
Rhea-AI Summary
Aurora Cannabis Inc. has acquired the remaining 90% equity interest of MedReleaf Australia for AUD$50 million, making it the largest global medical cannabis company operating in nationally legal markets. The transaction is expected to be immediately accretive to Adjusted EBITDA and accelerate the Company's plan for Positive Free Cash Flow generation in 2024. The Australian medical cannabis market is rapidly growing and is estimated to be worth approximately AUD$400 million, with MedReleaf Australia holding the #2 position in the market. The acquisition is a strategic milestone for Aurora, strengthening its presence in Australia and supporting its path to profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
acquisition
-
Rhea-AI Summary
Aurora Cannabis Inc. re-affirms its expectation of positive annual Adjusted EBITDA for fiscal 2024 and positive Free Cash Flow generation in calendar 2024. The company also announces its intention to consolidate common shares and schedules its Q3 2024 investor conference call for February 8, 2024. Adjusted EBITDA is expected to be positive on an annual basis in fiscal 2024, and management continues to expect positive free cash flow in calendar 2024. The Board of Directors has approved a plan to consolidate all outstanding Common Shares on the basis of 1 Common Share for every 10 Common Shares currently outstanding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.04%
Tags
earnings
-
Rhea-AI Summary
Aurora Cannabis Inc. (ACB) announces the launch of three new cannabis-infused beverages exclusively for veteran patients, available at Aurora Medical. The products, produced by Vacay and Versus, offer THC, CBD, and CBG options in three fruity flavors. The company aims to meet the needs of patients seeking alternative forms of cannabis to support their wellbeing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.31%
Tags
none
Rhea-AI Summary
Aurora Cannabis Inc. (ACB) achieved record positive adjusted EBITDA of $3.4 million, with quarterly net revenue rising 30% YoY to $63.4 million. The company also has a net cash position of over $200 million and expects to repay the remaining US$5.3 million balance of Convertible Senior Notes in February 2024. The Q2 2024 results show strong growth in global medical cannabis and a positive outlook for achieving positive free cash flow in calendar year 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.62%
Tags
earnings
Aurora Cannabis Inc

Nasdaq:ACB

ACB Rankings

ACB Stock Data

239.50M
54.39M
0.01%
6.96%
7.01%
Medicinal and Botanical Manufacturing
Manufacturing
Link
Canada
Edmonton

About ACB

aurora is a canadian company and licensed producer of artisanal medical marijuana pursuant to the marihuana for medical purposes regulations. we ensure the highest quality, reliability, and safety of our products through advanced cultivation techniques carried out in our 55,200 square foot expandable state-of-the-art production facility in alberta, canada. aurora’s wholly-owned subsidiary, australis capital inc., seeks to be an active participant in the u.s. cannabis market.